David J. Mack's most recent trade in BioXcel Therapeutics Inc was a trade of 1,693 Common Stock done . Disclosure was reported to the exchange on June 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| BioXcel Therapeutics Inc | David J. Mack | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2025 | 1,693 | 13,544 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | David J. Mack | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2025 | 1,693 | 6,773 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | David J. Mack | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 May 2025 | 1,693 | 8,466 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | David J. Mack | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 May 2025 | 1,693 | 11,851 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | David J. Mack | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 1,693 | 10,159 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | David J. Mack | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 1,693 | 10,158 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | David J. Mack | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2025 | 1,693 | 8,465 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | David J. Mack | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2025 | 1,693 | 11,852 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | David J. Mack | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 1,693 | 6,772 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | David J. Mack | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 1,693 | 13,545 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | David J. Mack | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 27,089 | 81,267 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | David J. Mack | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2025 | 27,089 | 243,810 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | David J. Mack | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 27,089 | 54,178 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | David J. Mack | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Dec 2024 | 27,089 | 270,899 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | David J. Mack | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Nov 2024 | 325,077 | 325,077 | - | - | Restricted Stock Units | |
| BioXcel Therapeutics Inc | David J. Mack | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Nov 2024 | 27,089 | 27,089 (0%) | 0% | - | Common Stock | |
| BioXcel Therapeutics Inc | David J. Mack | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Nov 2024 | 27,089 | 297,988 | - | - | Restricted Stock Units |